Pulmatrix Stops PUR1900 Phase 2B Study Patient Enrollment And Closing Study, In Agreement With Partner Cipla, To Preserve Cash And Facilitate Strategic Alternatives

Cipla to take sole responsibility for development of PUR1900, refocused on markets with greatest unmet need and faster path to approval, in exchange for 2% royalty on net sales payable to Pulmatrix 

Pulmatrix to significantly reduce cash burn and focus on strategic alternatives that leverage the company's promising pipeline, iSPERSE™ technology and approximately $19 million cash on hand as of 12/31/23